Although metastasis sequencing was not performed in our case, the primary-tumor profile (IDH1 mutation, TP53 mutation, ATRX loss, MGMT methylation) differs from the more typical metastasising GBM profile (IDH-wild-type with telomerase reverse transcriptase (TERT), EGFR, PTEN, CDKN2A/B alterations) [3]. The gene discussed is CDKN2A; the disease is neoplasm.